Literature DB >> 2917133

Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.

D A Lane1, H Erdjument, A Flynn, V Di Marzo, M Panico, H R Morris, M Greaves, G Dolan, F E Preston.   

Abstract

A Sheffield family with a predisposition towards thrombosis has been shown to have a functional abnormality of antithrombin. The abnormality was detected as reduced heparin cofactor activity, with normal antigenic levels of antithrombin. Crossed immunoelectrophoresis performed in the absence and presence of heparin was normal. The antithrombin was isolated by heparin Sepharose affinity chromatography. It had normal mobility on SDS polyacrylamide gel electrophoresis. However, the second order rate constant of inhibition of thrombin was about half that of normal, and this was compatible with a heterozygous abnormality involving the reactive site. The antithrombin was further purified by chromatography on thrombin-Sepharose (to remove the normal component), reduced, S-carboxymethylated and fragmented with cyanogen bromide. A pool containing the reactive site region was digested with trypsin and the molecular size of peptides generated determined by fast atom bombardment mass spectrometry. The two peptides adjacent to the Arg393-Ser394 bond of mass 2290 and 700 were almost absent from the mass spectrum, but an additional peptide of mass 2952 was present. Subdigestion with V8 protease reduced the mass of this peptide to 1748. These peptides generated by trypsin and V8 protease were almost identical to those obtained when another variant, antithrombin Glasgow, was treated in the same way (Erdjument et al, 1988). It is concluded that the molecular abnormality of antithrombin Sheffield is identical to that of antithrombin Glasgow, Arg393 to His.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917133     DOI: 10.1111/j.1365-2141.1989.tb06280.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Pleiotropic effects of antithrombin strand 1C substitution mutations.

Authors:  D A Lane; R J Olds; J Conard; M Boisclair; S C Bock; M Hultin; U Abildgaard; H Ireland; E Thompson; G Sas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  The genetics of venous thromboembolism: a systematic review of thrombophilia families.

Authors:  Yu Zhang; Zhu Zhang; Shi Shu; Wenquan Niu; Wanmu Xie; Jun Wan; Zhenguo Zhai; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

3.  Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function.

Authors:  Yang Liu; Colin A Kretz; Morgan L Maeder; Catherine E Richter; Philip Tsao; Andy H Vo; Michael C Huarng; Thomas Rode; Zhilian Hu; Rohit Mehra; Steven T Olson; J Keith Joung; Jordan A Shavit
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

Review 4.  Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer.

Authors:  Khue Vu Nguyen
Journal:  AIMS Neurosci       Date:  2022-04-21

5.  Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.

Authors:  P Molho-Sabatier; M Aiach; I Gaillard; J N Fiessinger; A M Fischer; G Chadeuf; E Clauser
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.